Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) - MDT-BRIDGE

Study identifier:D9106C00002

ClinicalTrials.gov identifier:NCT05925530

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants with Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Estimated Enrollment

140

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 31 Dec 2023
Estimated Primary Completion Date: 15 Mar 2027
Estimated Study Completion Date: 20 Sept 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria